OS THERAPIES INC
OSTXNYSE AMERICAN🏆 #3635 by market capEarnings Aug 17US Equity
$1.61▲ $0.01 (+0.63%)
Live1h—
24h▲ 0.6%
7d▼ 0.6%
14d▲ 8.8%
30d▼ 0.6%
1y▼ 9.6%
🏦Market Cap
$73M
Small Cap
📈Revenue Growth (YoY)
—
📊Gross Margin
—
💵FCF Margin
—
⚖️P/S Ratio
—
Otter Score
44
Weak
Trading Snapshot
- Day Range
- $1.58 – $1.62
- 52-Week Range
- $1.15 – $2.57
- Volume
- $2.43B
- Avg Volume
- $2.82B
- Shares Outstanding
- 45.5M
- Next Earnings
- Oct 9, 2026
Fundamentals Snapshot
- Annual Revenue
- $5M
- Last Q Revenue
- $1M
- P/E Ratio
- —
- P/S Ratio
- —
- EPS (TTM)
- $-1.05
- Dividend Yield
- —
Why Investors Own OSTX
- ✓High-growth profile — revenue up +12.2% YoY with expanding US Equity exposure.
- ✓Healthy economics — 58% gross margin and 16% free-cash-flow margin.
- ✓New products and segments could unlock additional revenue streams.
⚠️ Key Risks
Execution delays, intensifying competition, and valuation compression if growth decelerates.
Financial Trends
Revenue (TTM)
$5M▲ +12.4% YoY
Gross Margin (TTM)
57.9%▲ +0.1% YoY
Operating Income (TTM)
$2M▲ +12.4% YoY
Free Cash Flow (TTM)
$781,750▲ +12.4% YoY
About OS THERAPIES INC
OS Therapies Incorporated, a clinical stage biopharmaceutical company, focuses on the identification, development, and commercialization of treatments for osteosarcoma and other solid tumors in the United States. Its pipeline includes OST-HER2, an off-the-shelf immunotherapy for osteosarcoma patients; and OST-tunable drug conjugate (OST-tADC), an antibody-drug conjugate (ADC) silicone dioxide linker technology, with a plug-and-play platform that features tunable pH sensitive silicone linkers. OS Therapies Incorporated was incorporated in 2018 and is based in Grasonville, Maryland.
🦦
Otter Score Breakdown
ⓘ💎Quality★★★★★
🚀Growth★★★★★
⚖️Valuation★★★★★
⚡Momentum★★★★★
Overall Score
Weak
44/100
Analyst Ratings
ⓘConsensus
Buy
10 analysts
Strong Buy2
Buy7
Hold1
Sell0
Strong Sell0
Ratings as of Aug 2026